Clinica Oculistica, Department of Neurosciences, Ophthalmology, and Genetics, University of Genoa, Genoa, Italy.
J Ocul Pharmacol Ther. 2011 Jun;27(3):281-5. doi: 10.1089/jop.2010.0133. Epub 2011 May 10.
The purposes of this study were to evaluate the presence of symptoms of tear film dysfunction by using the Ocular Surface Disease Index (OSDI) questionnaire in glaucomatous patients and to examine whether they have ocular surface signs.
Fifty patients with ocular hypertension or open-angle glaucoma were sequentially examined. All patients used preserved antiglaucomatous drops once, twice, 3 times, or 4 times a day. Each patient filled out an OSDI questionnaire. Fluorescein corneal staining, lissamine green conjunctival staining, break-up time, and Schirmer I test were performed in patients with positive OSDI.
Using the OSDI, 26 of 50 patients (52%) showed at least mild symptoms of tear film dysfunction (score >12); of them, 17 (34%) had severe OSDI (Score >32). Decrease in tear production was seen in only 8 glaucomatous patients. The break-up time was <7 s in 18 patients. Lissamine green conjunctival staining was positive in at least one eye of all the 26 patients, whereas fluorescein corneal staining was positive in at least one eye of 22 patients. A statistically significant (P<0.05) difference was found for lissamine green conjunctival staining between 16 patients using ipotensive drops once or twice a day and 10 patients using drops 3 or 4 times a day. In the group of patients using only β-blocker agents, we found a positive correlation between symptoms and vital staining of the ocular surface.
Fifty-two percent of patients in therapy with preserved antiglaucomatous drops showed symptoms of tear film dysfunction. Signs of ocular surface diseases seemed to be greater in patients under >2 medications. Symptoms correlated to signs only in patients in monotherapy with β-blockers drops.
本研究旨在通过使用眼表疾病指数(OSDI)问卷评估青光眼患者泪膜功能障碍的症状,并检查他们是否存在眼表体征。
对 50 名高眼压或开角型青光眼患者进行连续检查。所有患者每天使用防腐剂抗青光眼滴眼液 1、2、3 或 4 次。每位患者填写一份 OSDI 问卷。对 OSDI 阳性患者进行荧光素角膜染色、丽丝胺绿结膜染色、泪膜破裂时间和 Schirmer I 试验。
使用 OSDI,50 名患者中有 26 名(52%)至少出现轻度泪膜功能障碍症状(评分>12);其中 17 名(34%)出现严重 OSDI(评分>32)。仅 8 名青光眼患者出现泪液分泌减少。18 名患者的泪膜破裂时间<7 秒。26 名患者中至少有一只眼的丽丝胺绿结膜染色阳性,而至少有一只眼的荧光素角膜染色阳性的患者有 22 名。每天使用 1 或 2 次降压滴眼剂的 16 名患者与每天使用 3 或 4 次滴眼剂的 10 名患者之间,丽丝胺绿结膜染色的差异有统计学意义(P<0.05)。在仅使用β受体阻滞剂的患者组中,我们发现症状与眼表面活力染色之间存在正相关。
在使用防腐剂抗青光眼滴眼剂治疗的患者中,有 52%的患者出现泪膜功能障碍症状。接受>2 种药物治疗的患者眼表面疾病迹象似乎更大。在仅接受β受体阻滞剂滴眼剂治疗的患者中,症状与体征相关。